NCT06685068 2026-04-14
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
Genmab
Phase 1/2 Terminated
Clinical Trials
12 trialsNCT05756907 2026-02-03
Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
Sonnet BioTherapeutics
Phase 1/2 Terminated
NCT04284488 2026-01-08
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
Ascentage Pharma Group Inc.
Phase 1/2 Terminated
NCT05821777 2025-09-25
A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors
Centessa Pharmaceuticals plc
Phase 1/2 Terminated
NCT06226766 2025-09-10
JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2 Terminated
NCT05109442 2025-08-20
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
Affimed GmbH
Phase 1/2 Terminated
NCT04259450 2025-07-17
Study to Assess AFM24 in Advanced Solid Cancers
Affimed GmbH
Phase 1/2 Terminated
NCT05580770 2025-02-17
Mirdametinib + BGB-3245 in Advanced Solid Tumors
SpringWorks Therapeutics, Inc.
Phase 1/2 Terminated
NCT05148533 2024-04-15
A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor
TJ Biopharma Co., Ltd.
Phase 1/2 Terminated
NCT05255484 2023-10-25
Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
Phase 1/2 Terminated
NCT04471415 2023-06-12
Study to Investigate DRP-104 in Adults With Advanced Solid Tumors
Dracen Pharmaceuticals, Inc.
Phase 1/2 Terminated
NCT05008445 2023-03-09
Study of LM-102 in Patients With Advance Solid Tumors
LaNova Medicines Limited
Phase 1/2 Terminated